Home Cart 0 Sign in  
X

[ CAS No. 73568-25-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 73568-25-9
Chemical Structure| 73568-25-9
Chemical Structure| 73568-25-9
Structure of 73568-25-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 73568-25-9 ]

Related Doc. of [ 73568-25-9 ]

Alternatived Products of [ 73568-25-9 ]

Product Details of [ 73568-25-9 ]

CAS No. :73568-25-9 MDL No. :MFCD00130079
Formula : C10H6ClNO Boiling Point : -
Linear Structure Formula :- InChI Key :SDKQWXCBSNMYBN-UHFFFAOYSA-N
M.W : 191.61 Pubchem ID :690958
Synonyms :

Calculated chemistry of [ 73568-25-9 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 52.14
TPSA : 29.96 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.62 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.82
Log Po/w (XLOGP3) : 2.61
Log Po/w (WLOGP) : 2.7
Log Po/w (MLOGP) : 1.7
Log Po/w (SILICOS-IT) : 3.22
Consensus Log Po/w : 2.41

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.18
Solubility : 0.128 mg/ml ; 0.000668 mol/l
Class : Soluble
Log S (Ali) : -2.89
Solubility : 0.248 mg/ml ; 0.00129 mol/l
Class : Soluble
Log S (SILICOS-IT) : -4.27
Solubility : 0.0103 mg/ml ; 0.000054 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.38

Safety of [ 73568-25-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 73568-25-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 73568-25-9 ]
  • Downstream synthetic route of [ 73568-25-9 ]

[ 73568-25-9 ] Synthesis Path-Upstream   1~22

  • 1
  • [ 73568-25-9 ]
  • [ 13669-51-7 ]
YieldReaction ConditionsOperation in experiment
84% With hydrogen; sodium acetate; palladium dichloride In methanol at 35℃; for 3 h; Typical procedures: 6-bromonicotinaldehyde (930 mg, 5.0 mmol), NaOAc (820 mg, 10.0 mmol), MeOH (30 mL), and PdCl2 (45 mg) were mixed in a glass bottle capped with a balloon filled with hydrogen. After stirred at 35 °C for 4 h, the mixture was filtered and washed with MeOH. The solvent was removed and the residue was dissolved in water, neutralized with solid NaHCO3, and extracted with ethyl acetate. The organic phase was dried over anhyd Na2SO4, and then filtered. The solvent was removed and the residue was subjected to chromatography to yield pyridin-3-ylmethanol (428 mg, 78percent).
Reference: [1] Tetrahedron Letters, 2012, vol. 53, # 29, p. 3798 - 3801
[2] Journal of the American Chemical Society, 1990, vol. 112, # 11, p. 4431 - 4435
[3] Journal of the American Chemical Society, 1990, vol. 112, # 11, p. 4431 - 4435
  • 2
  • [ 73568-25-9 ]
  • [ 95104-21-5 ]
YieldReaction ConditionsOperation in experiment
82% With ammonium hydroxide; ammonium cerium (IV) nitrate; hydroxylamine hydrochloride In water at 0℃; A suspension of 2-chloroquinoline-3-carbaldehyde (0.01 mol) in30percent aqueous ammonia (30 mL) was stirred for 5 min at room temperature,resulting in formation of a turbid solution. To this, cericammonium nitrate (0.01 mol) was added with constant stirring at0 C. After completion of the reaction (monitored by TLC, 10–15 min), the mixture was extracted with chloroform–ethyl acetate(5:3), dried with anhydrous sodium sulfate, and concentrated underreduced pressure to give a crude product, which was crystalized inethanol to give pure 2-chloroquinoline-3-carbonitrile as pale yellowcrystals. Yield: 82percent.
58% With pyridine; ammonium peroxydisulfate; tris(2,2-bipyridine)ruthenium(II) hexafluorophosphate; 4-acetylamino-2,2,6,6-tetramethyl-1-piperidinoxy In acetonitrile at 0.5℃; for 24 h; Molecular sieve; Sealed tube; Irradiation General procedure: To an oven-dried 2 ml reaction vial equipped with a stir bar wasadded the aldehyde 3a (0.136 g, 1 mmol, 1 equiv) and pyridine(0.474 g, 6.0 mmol, 6 equiv), followed by acetonitrile (2 ml, 0.5M in 3a). The vial was then charged with Ru(bpy)3(PF6)2 (0.017g, 0.02 mmol, 0.02 equiv), 2 (0.043 g, 0.20 mmol, 0.20 equiv),(NH4)2S2O8(0.501 g, 2.2 mmol, 2.2 equiv), and activated 3 Åmolecular sieves (ca. 0.2 g), sealed with a cap, and irradiated inblue LED reactor for 24 h. In the absence of fan cooling, the temperatureof the reaction mixture plateaued at approximately 50°C . After the irradiation was complete, the reaction mixturewas quenched with EtOAc and transferred to a separatoryfunnel. Further EtOAc (30 ml) was added, followed by 0.5 MHCl(aq) (30 ml). The layers were separated, and the aqueous layerwas extracted with EtOAc (3 × 20 ml). The organic layers werethen combined and washed with 0.5 M 0.5 M HCl(aq) (2 × 20 ml),saturated aqueous sodium bicarbonate (2 × 20 ml), and finallybrine (20 ml). The organic layer was then dried over sodiumsulfate and the solvent removed in vacuo to afford the crudeproduct. The resulting crude mixture was adhered to silica gelusing 1.5 weight equivalents of SiO2(relative to the theoreticalyield). The dry-packed material was gently added on top of asilica gel plug. The plug was washed with an excess of hexanes(ca. 5 column volumes). The desired product was eluted off theplug via a 90:10 by volume mixture of hexanes/EtOAc (3–4column volumes). The solvent was removed in vacuo by rotaryevaporation affording the pure nitrile 3c (0.066 g, 50percent) as awhite solid.
Reference: [1] Synlett, 2009, # 20, p. 3378 - 3382
[2] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 9, p. 1868 - 1875
[3] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 1, p. 292 - 296
[4] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 1, p. 152 - 154
[5] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 3, p. 602 - 611
[6] Synlett, 2018, vol. 29, # 16, p. 2185 - 2190
[7] Journal of Chemical Research - Part S, 2000, # 1, p. 30 - 31
[8] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 9, p. 1868 - 1875
[9] Archiv der Pharmazie, 2001, vol. 334, # 4, p. 117 - 120
[10] Patent: US4496569, 1985, A,
[11] Journal of Heterocyclic Chemistry, 2011, vol. 48, # 5, p. 1202 - 1205
[12] Tetrahedron, 2011, vol. 67, # 47, p. 9219 - 9224
[13] Indian Journal of Heterocyclic Chemistry, 2012, vol. 21, # 3, p. 237 - 244
[14] European Journal of Medicinal Chemistry, 2017, vol. 126, p. 894 - 909
[15] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 13, p. 2244 - 2249
  • 3
  • [ 73568-25-9 ]
  • [ 73776-25-7 ]
YieldReaction ConditionsOperation in experiment
90% With tert.-butylhydroperoxide In 1,2-dichloro-ethane at 80℃; for 7 h; General procedure: A Solution of 2-(phenylethynyl)quinoline-3-carbaldehyde 1 (0.5 mmol), TBHP (4.0 equiv.) and DCE (2.0 mL) was heated at 80 °C for 6 to 8h in aerobic atmosphere. After completion of the reaction, solvent was evaporated under reduced pressure. Water was added to the reaction mixture and extracted with EtOAc. Organic phase was washed with water, brine and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure and obtained residue was purified by column chromatography (hexane: ethyl acetate = 15:5) to afford 2.
84% With potassium permanganate; sodium hydroxide In water; <i>tert</i>-butyl alcohol at 70 - 80℃; for 4 h; To a solution of aldehyde 1[46] (3.8 g, 20 mmol) in a mixture of H2O/t-butanol (1 : 1, 30 mL) was added a solution of KMnO4 (4.0 g, 25 mmol) in H2O (30 mL) at 70–80 °C over 30 min. Then, a solution of NaOH (10percent, 30 mL) was added with stirring until the solution turned alkaline. The reaction mixture was stirred at the same temperature for 4 h. The reaction mixture was filtered and the resulting clear filtrate was acidified with HCl solution (40 mL, 30percent). The resulting acid was purified by dissolving in NaHCO3 solution (50 mL, 10percent) and the whole solution was filtered on hot and then neutralized with dilute HCl. The resulting precipitate was filtered, washed with water, and dried to give (3.6 g, 88percent) of crude acid. Crystallization from methanol gave 3.4 g (84percent) of pure 2-chloroquinoline-3-carboxylic acid (2) as white crystals, mp 178–180 °C (lit. 181–182 °C[47]). νmax (KBr)/cm-1 3090, 2980, 2950, 1720, 1605, 1585, 1460, 1435, 1395, 1225, 745. δH (90 MHz, CDCl3) 6.8–8.0 (m, 5H, Ar–H), 10.5 (s, 1H, COOH). δC (100 MHz, CDCl3) 126.6 (1C,Ar, C-4a), 127.1 (1C, Ar, C-6), 127.2 (1C, Ar, C-5), 128.0 (1C, Ar, C-8), 128.8 (1C, Ar, C-3), 129.0 (1C, Ar, C-7), 129.6 (1C, Ar, C-4), 149.4 (1C, Ar, C-8a), 151.0 (1C, Ar, C-2), 165.5 (1C, COOH). m/z (EI, 70 eV) (percent) 209 (M++2, 18), 207 (45), 190 (100), 172 (30), 162 (64), 127 (32), 104 (16), 91 (50), 76 (18). Anal. Calc. for C10H6ClNO2 (207.5): C 57.83, H 2.89, N 6.74, Cl, 17.10. Found: C 57.73, H 2.91, N 6.80 Cl, 17.28percent.
67%
Stage #1: With sodium hydroxide; silver nitrate In ethanol; water at 20℃; for 4.25 h;
Stage #2: With hydrogenchloride In water
A suspension of silver nitrate (6.8 g, 40 mmol) in ethanol (100 mL) was added to a solution of 2- chloro-quinoline-3-carbaldehyde (4.8 g, 25 mmol) in ethanol (200 mL). A solution of sodium hydroxide (5 g, 125 mmol) in 80percent ethanol (100 mL) was added over 15 minutes. The resulting black suspension was stirred at ambient temperature for 4 hours. The mixture was filtered through a pad of celite, and the pad was washed generously with ethanol. The combined ethanolic solutions were concentrated in vacuo and diluted with water. The aqueous solution was neutralized with concentrated hydrochloric acid, and the product precipitated. The product was collected by filtration and washed with water. The solid was triturated in hot ethanol, cooled and collected by filtration to give a colorless solid, 3.5 g (67percent). MS: m/z 208 (MH+). 1H NMR (DMSO-D6) : δ 7. 74 (d of d, 1 H), 7.94 (d of d, 1 H), 8.01 (d, 1 H), 8.18 (d, 1 H), 8.95 (s, 1 H) and 13.81 (s, 1 H).
60.5% With sodium chlorite; sodium dihydrogenphosphate dihydrate In acetonitrile at 20℃; 2-chloro-3-quinolinecarboxaldehyde (23.48 mmol, 4.5g) was suspended in MeCN (100 ml) and a solution of sodium dihydrogen phosphate dihydrate (1 17 mmol, 94 ml) was added followed by sodium chlorite (70.5 mmol, 6.37 g). The reaction was stirred at rt overnight and then quenched by the addition of sodium sulfite (96 mmol, 96 ml) followed by stirring for 1 h. The aqueous layer was acidified with 2M HCI to pH -3 and extracted with EtOAc (2 x 200ml). The organic layers were combined, dried over Na2S04 and concentrated in vacuo to afford 2-chloroquinoline-3-carboxylic acid as a pale yellow solid (60.5 percent, 2.95 g, 14.21 mmol), M.S. (ESI) (m/z): 208[M+H]+.
26% With sodium acetate In acetonitrile at 80℃; Sonication General procedure: Compounds 17a, 15a and 18e were subjected to the above reaction conditions but using 3-butyl-4-methylthiazolium chloride instead of the imidazolium salt. After solvent was removed under reduced pressure, the resulting solid was dissolved in H2O and neutralized with 20percent HCl. The precipitate formed was filtered and washed with water to afford compounds 23a and 24a,e.

Reference: [1] Tetrahedron Letters, 2018, vol. 59, # 11, p. 1019 - 1022
[2] Green Chemistry, 2012, vol. 14, # 6, p. 1649 - 1656
[3] Journal of Medicinal Chemistry, 2014, vol. 57, # 24, p. 10329 - 10342
[4] Australian Journal of Chemistry, 2017, vol. 70, # 10, p. 1082 - 1092
[5] Journal of Heterocyclic Chemistry, 1991, vol. 28, # 5, p. 1339 - 1340
[6] Patent: WO2004/69792, 2004, A2, . Location in patent: Page 129-130
[7] Patent: WO2011/61318, 2011, A1, . Location in patent: Page/Page column 45
[8] Tetrahedron Letters, 2014, vol. 55, # 31, p. 4395 - 4399
[9] Patent: US2005/171114, 2005, A1, . Location in patent: Page/Page column 16
[10] Molecules, 2016, vol. 21, # 7,
[11] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 4, p. 1002 - 1009
  • 4
  • [ 68-12-2 ]
  • [ 103-84-4 ]
  • [ 73568-25-9 ]
YieldReaction ConditionsOperation in experiment
91.62% With bis(trichloromethyl) carbonate In chloroform at -5 - 40℃; for 4.66667 h; Green chemistry This example provides a process for the synthesis of 2-chloro-3-formylquinoline with the following main steps: under ice-salt bath, 2.73 g (20.22 mmol) acetanilide, 8.19 g (27.58 mmol) of BTC and 10 mL of trichloromethane 4.2 mL (54.66mmol) DMF was added dropwise over 30 min after the temperature was maintained below -5 °C. The rate of the bubble overflow was controlled by the tail gas uptake rate. After the addition of the DMF, the mixture was stirred continuously for 10 min. For water bath, plus Heat to 40 °C, reaction 4 hours, steaming part of the solvent, adding ice water, 10percent NaOH to adjust the pH to 8 ~ 9, pumping, ethyl acetate recrystallization. The yield was 91.62percent.
90% at 0℃; Heating Dry DMF (3mmol) was cooled to 0°C in a flask equipped with a drying tube and then POCl3 (12mmol) was added drop-wise with stirring. To this solution, acetanilide (1mmol) was added in small portions and after 25–30min the reaction mixture was heated for 24h on a boiling water bath. The reaction mixture was poured into ice water and stirred for 30min. The work-up was performed with aqueous NaOH to form a precipitate, to hydrolyse the imine salt and remove any acid formed. The solid was filtered, dried and purified from ethyl acetate to give 2-chloro-3-formyl quinoline in high yield (90percent).
89% at 80 - 90℃; for 12 h; To stirred DMF (3.6 mL, 46 mmol), 12.5 mL POCl3 (134 mmol) were added dropwise at 0-5 °C. The mixture was allowed to stir for 30 min. Acetanilide 2 (18.5 mmol) was then added and the resulting solution heated for 12 h at 80-90 °C. The mixture was poured into ice-cold water and stirred for 10 min, which resulted in yellow precipitation of the desired 2-chloroquinoline-3-carbaldehydes 3. The precipitate was filtered and washed with water and then dried. The compounds were purified by recrystallization from ethyl acetate.
87% at 0 - 65℃; for 8 h; Inert atmosphere At 0 C to a stirred solution of POCl3 (39.6 g, 259 mmol) and anhydrous DMF (8 g, 111 mmol) was added acetanilide (5 g, 37 mmol). The mixture was then heated to 65 C, and the progress of the reaction was monitored by thin-layer chromatography (TLC) analysis. After 8 h the reaction mixture was cooled to room temperature and added cautiously into ice-cold water. The precipitated solid was collected by filtration to isolate compound 1a as yellow solid. Yield 6.2 g (87 percent), yellow solid.
87% at 0 - 65℃; for 8 h; General procedure: At 0 °C to a stirred solution of POCl3 (39.6 g, 259 mmol) and anhydrous DMF (8 g, 111mmol) was added acetanilide (5 g, 37 mmol). The mixture was then heated to 65 °C and the progress of the reaction was monitored by TLC analysis. After 8 h the reaction mixturewas then cooled to room temperature and added cautiously into ice-cold water. The solid precipitated was collected by filtration to isolate the compound 1a as yellow solid.
82% at 85 - 90℃; Reflux Synthesis of 2-chloroquinoline-3-carbaldehyde (4a) [44–55]
To a stirred solution of N-phenylacetamide(3a) (5 mmoles) in dry DMF (15 mmoles), POCl3 (60 mmoles) was added drop-wise.
The mixture was refluxed for overnight on water bath at 85-90 °C.
The reaction mixture was quenched with crushed ice present in a 500 mL beaker and stirred well for some time.
The precipitate obtained was filtered, dried and purified by recrystallization processby using ethyl acetate to afford pure compound 4a in 82percent yield.
Similarly, the other aldehydes 4b-c were prepared by using the procedures reported earlier.
79% at 80 - 100℃; To a s o l u t i o n o f a c e t a n i l i d e(N-phenylacetamide) (5 mmoles) in dry DMF (15mmoles) at 0-5oC POCl3 (60 mmoles) was addeddropwise with stirring and the mixture was thenstirred at 80 – 100oC for time ranging between 4-16hr. The mixture was poured on to crush ice, stirredfor 5 minutes and the resulting solid fltered, washedwell with water and dried. The compounds wererecrystallized from ethyl acetate. Phosphoryl chloride(commonly called phosphorus oxychloride) is acolorless liquid with the formula POCl3. It hydrolysesin moist air to phosphoric acid to release choking fumes of hydrogen chloride. It is manufacturedindustrially on a large scale from phosphorustrichloride and oxygen or phosphorus pentoxide. Itis mainly used to make phospha (Table 1).
72%
Stage #1: at 0℃; for 0.25 h;
Stage #2: for 4 h; Reflux
General procedure: Dimethylformamide (12 mmol, 3 equiv.) was cooled at 0°C in a round flask equipped with a drying tube and phosphorus pentachloride (18 mmol, 4.5 equiv.) was added slowly and the mixture was stirred for 15 minutes keeping the temperature below 0°C. To this solution was added in a portion the corresponding acetanilide (4 mmol, 1 equiv.) and the reaction mixture was heated under reflux and stirring for the appropiate time depending of the acetanilide. The resulted mixture was cooled to 0°C and the solution was poured slowly into ice-water and stirring for ten minutes, obtaining a yellow solid which was filtered, washed several time with cold water and dried under vacuum. The 2-chloroquinoline-3-carbaldehydes were recrystallized according to the literature. 2-Chloroquinoline-3-carbaldehyde (5a): Recristalization eluent: Ethyl acetate; Yield 552 mg (72percent); yellow pale solid, mp 145-146 C. IR (KBr): 3043 (st. C-H), 2872 (st. C-H), 1688 (st.C=O), 1615-1553 (st. C=C) cm-1. 1H-NMR (270 MHz, J Hz, CDCl3) δ: 10,55 (s, 1H); 8,76 (s,1H); 8,07 (d, J=8,6; 1H); 7,98 (d, J=7,9; 1H); 7,89 (dd, J1=8,3; J2=7,7; 1H); 7,64 (dd, J1=8,3;J2= 7,9; 1H). 13C-NMR (100 MHz, CDCl3) δ: 189,4 (d); 150,3 (s); 140,5 (d); 133,7 (d); 130,6(s); 129,6 (s); 129,1 (d); 127,7(d); 126,6 (d); 121,2. Anal. Calcd for C10H6ClNO: C, 62,48; H,3,11; N, 7,23 percent. Found: C, 62,68; H, 3,16; N, 7,31 percent.
72% at 0 - 80℃; General procedure: [00119] Acetanilide (2a)/substituted acetanilides (2b - 2h) (0.05 mol) were dissolved in 9.6 ml of dimethyl formamide (0.125 mol) and to this solution, 32 ml of phosphorus oxychloride (0.35 mol) was added gradually at 0 °C. The reaction mixture was taken in a round bottom flask (RBF) equipped with a reflux condenser fitted with a drying tube and was heated for 4-16 hours on oil bath at 75-80 °C. The solution was then cooled to room temperature and subsequently poured onto 100 ml of ice water. The precipitate formed was collected by filtration and recrystallized from ethyl acetate.
68% at 65℃; for 16 h; Example 35; Synthesis of (3,5-bis-trifluoromethyl-benzyl)- [2-(cyclopentylmethyl-ethyl-amino)- quinolin-3-ylmethyl]-carbamic acid methyl ester; Step (i): Synthesis of 2-chloroquinoline-3-carbaldehyde:; Dimethylformamide (9.13 grams, 0.125 mol) was cooled to 0 0C in a flask equipped with a drying tube, and phosphorous oxychloride (53.7 grams, 0.35 mol) was added drop-wise with stirring. To this solution was added acetanilide (6,55 grams, 0.05 mol) and the mixture was heated under reflux for 16 hours at 65 0C. Excess phosphorous oxychloride was distilled off, water was added, and the solution was extracted with ethyl acetate. The solvent was evaporated and the crude purified over silica gel (100-200 mesh) using 2percent ethyl acetate/petroleum ether. Yield: 68percent, mp: 145 0C;1H NMR (CDCl3, 400 MHz): d 10.5 (s, IH); 8.78 (s, IH), 8.12-7.90 (m, 3H); 7.70 (t, J =7.3 Hz, IH);Mass m/z (EI-MS): 192 (M+l, 100percent).
65% at 0 - 90℃; for 12 h; 2-Chloroquinoline-3-carbaldehyde was synthesized from acetanilide via Vilsmeier–Haack reaction (Srivatava and Singh, 2005). To a solution of acetanilide (0.005 mol; 0.67 g) in dry dimethylformamide (0.015 mol; 1.09 ml) at 0–5 °C with stirring, phosphorous oxychloride (0.06 mol; 5.59 ml) was added drop wise and the mixture stirred at 80–90 °C for 12 h. The mixture was poured into crushed ice and stirred for 5 min, and the resulting solid filtered was washed well with water and dried. The compound was purified by recrystallization from ethyl acetate. It was obtained as yellow solid, yield 65 percent; m.p. 146–148 °C; IR(KBr) vmax 2871, 1687, 749 cm-1; 1H NMR (DMSO,300 MHz): δ = 10.25 (s, 1H, CHO), 7.70 (t, 1H, J = 6.2,H-7), 7.25 (d, 1H, J = 6.5 Hz, H-6), 6.89 (d, 1H,J = 6.3 Hz, H-8), 6.78 (t, 1H, J = 7.1 Hz, H-5); 13C NMR(DMSO, 75 MHz): δ = 190 (CH, –CHO), 153 (C, C-2),145.4 (CH, C-4), 134 (CH, C-8), 129.8 (C, C-3), 129.3(CH, C-6), 128.5 (C, C-5), 128 (CH, C-9), 127.2 (CH, C-5); EIMS m/z: 191.01 (M+); Anal. Calcd. for C10H6ClNO: C,62.68; H, 3.16; N, 7.31. Found: C, 62.71; H, 3.18; N, 7.33.
65% at 80℃; for 8 h; Acetanilide (15.6 mmol, 1.0 eq) (14) was treated with POCl3(156.0 mmol, 10.0 eq.) and DMF (51.48 mmol, 3.3 eq.) at 80 °C for 8 h.The reaction mixture was cooled to room temperature (40 °C) andpoured into crushed ice under stirring. Pale yellow precipitates wereformed, which were washed with cold water several times and dried togive 2-chloro-quinoline-3-carbaldehyde (15). 2-Chloro-quinoline-3-carbaldehyde (15): yellow solid, yield 65percent,m.p. 150–151 °C; IR (KBr): max cm−1 3043, 2872, 1722, 1684, 1567,1489, 760, 748; 1H NMR (CDCl3, 400 MHz): δ 10.55 (s, 1H), 8.74 (s,1H), 8.06 (d, 1H, J=8.5 Hz), 7.98 (d, 1H, J=8.2 Hz), 7.88 (ddd, 1H, J=1.4, 7.0 and 8.4 Hz), 7.65 (td, 1H, J=1.0 and 7.6 Hz); 13C NMR(CDCl3, 100 MHz): δ 189.1, 150.1, 149.6, 140.3, 133.6, 129.7, 128.6,128.1, 126.5, 126.4; ESI-MS found m/z 191.96 [M+H]+ and 193.98[M+H+2]+.
64% at 0 - 75℃; for 16.5 h; Dimethyl formamide (9.6 mL, 0.125 mol) was cooled to 0 C in aflask equipped with a drying tube, and phosphoryl chloride(32.2 mL, 0.35 mol) was added dropwise with stirring. To this solution,acetanilide (0.05 mol) was added, and, after 5 min, the solutionwas heated under reflux at 75 C for 16.5 h in a temperaturecontrolledoil bath. After completion of the reaction, as indicated by TLC, the solution was cooled to room temperature and pouredinto 100 mL of ice water. The precipitate was collected by filtrationand recrystallized from ethyl acetate to yield 2-chloroquinoline-3-carbaldehyde as pale yellow crystals. 64percent yield.
60%
Stage #1: for 0.333333 h; Cooling
Stage #2: at 90℃; for 12 h;
General procedure: N,N-Dimethylformamide (0.025 mol) was cooled in an ice-salt bath and treated with phosphorylchloride (0.070 mol) for 20 min. The resulting mixture was added dropwise to a cooled solution ofthe appropriate acetylated aniline (8–10) (0.010 mol) in N,N-dimethylformamide (10 mL) with stirring.The mixture was stirred at 90 C for 12 h. A small amount of crushed ice was added and the mixturewas basified to pH 14 with 5 M NaOH. After stirring at ambient temperature for 1 h, the precipitatewas filtered, washed with water, and dried to give the title compound. 2-Chloroquinoline-3-carbaldehyde (5) [76]. Yellow solid, yield: 60percent; m.p. 150–152 C (lit. [76] m.p.146–149 C); 1H-NMR (CDCl3): 10.59 (1H, s, CHO), 8.79 (1H, s, H4), 8.11–7.65 (4H, m, H5, H6,H7, H8).
49%
Stage #1: at 0℃; for 0.0833333 h;
Stage #2: at 75℃; for 12 h;
POCI3 (1.29 mL, 14.1 mmol, 9.5 eq) was added to DMF (0.379 mL, 4.89 mmol, 3.3 eq) at 0°C. The mixture was stirred for an additional 5 minutes at 0°C before the addition of N-phenylethanamide (200 mg, 1 .48 mmol). The mixture was then heated to 75°C and stirred for 12 hours. Upon completion, the reaction was quenched very carefully with cold water and extracted 3 times with Et20. The combined organic layers were dried (MgSO4), concentrated, and the crude material was purified by combiflash 0->30percent EtOAc in hexanes to provide 2-chloroquinoline-3-carbaldehyde (139 mg, 49percent yield).

Reference: [1] Patent: CN106831566, 2017, A, . Location in patent: Paragraph 0005; 0022-0033
[2] Tetrahedron Letters, 1997, vol. 38, # 28, p. 4969 - 4972
[3] Synlett, 2001, # 2, p. 251 - 253
[4] Journal of Photochemistry and Photobiology B: Biology, 2016, vol. 165, p. 266 - 276
[5] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 2, p. 365 - 371
[6] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 7, p. 1253 - 1260
[7] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5379 - 5388
[8] Asian Journal of Chemistry, 2015, vol. 27, # 10, p. 3667 - 3670
[9] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 635 - 646
[10] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 647 - 658
[11] Journal of Organometallic Chemistry, 2015, vol. 798, p. 125 - 131
[12] Synthetic Communications, 2002, vol. 32, # 9, p. 1351 - 1356
[13] Letters in Organic Chemistry, 2011, vol. 8, # 1, p. 53 - 59
[14] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 9, p. 1868 - 1875
[15] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2006, vol. 45, # 1, p. 292 - 296
[16] Journal of Molecular Structure, 2014, vol. 1070, # 1, p. 10 - 20
[17] Synlett, 2006, # 16, p. 2593 - 2596
[18] Tetrahedron, 2009, vol. 65, # 34, p. 7099 - 7104
[19] Journal of Sulfur Chemistry, 2011, vol. 32, # 5, p. 475 - 481
[20] Chinese Journal of Chemistry, 2016, vol. 34, # 4, p. 403 - 411
[21] Synlett, 2000, # 8, p. 1115 - 1118
[22] Oriental Journal of Chemistry, 2016, vol. 32, # 4, p. 1977 - 1982
[23] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1981, p. 1520 - 1530
[24] Tetrahedron Letters, 2008, vol. 49, # 17, p. 2810 - 2814
[25] Synthetic Communications, 2016, vol. 46, # 3, p. 287 - 291
[26] Patent: WO2017/83979, 2017, A1, . Location in patent: Paragraph 00117; 00119; 00122
[27] Chemistry of Heterocyclic Compounds, 2017, vol. 53, # 4, p. 434 - 445[28] Khim. Geterotsikl. Soedin., 2017, vol. 53, # 4, p. 434 - 445,12
[29] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2002, vol. 41, # 2, p. 433 - 435
[30] Patent: WO2006/73973, 2006, A2, . Location in patent: Page/Page column 197-198
[31] Journal of Physical Organic Chemistry, 2011, vol. 24, # 3, p. 203 - 211
[32] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 10, p. 1491 - 1495
[33] Journal of the Brazilian Chemical Society, 2011, vol. 22, # 9, p. 1742 - 1749
[34] Synlett, 2011, # 1, p. 84 - 88
[35] Medicinal Chemistry Research, 2014, vol. 24, # 6, p. 2514 - 2528
[36] Bioorganic Chemistry, 2018, vol. 80, p. 591 - 601
[37] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 3, p. 602 - 611
[38] Synthetic Communications, 2006, vol. 36, # 23, p. 3581 - 3589
[39] Molecules, 2016, vol. 21, # 7,
[40] Archiv der Pharmazie, 2006, vol. 339, # 5, p. 242 - 249
[41] Patent: WO2015/51149, 2015, A1, . Location in patent: Paragraph 0091; 0092
[42] Synthetic Communications, 2004, vol. 34, # 11, p. 2019 - 2024
[43] Synthetic Communications, 2005, vol. 35, # 21, p. 2779 - 2788
[44] Tetrahedron Letters, 2006, vol. 47, # 44, p. 7779 - 7782
[45] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2007, vol. 46, # 2, p. 303 - 307
[46] Synlett, 2007, # 12, p. 1873 - 1876
[47] Phosphorus, Sulfur and Silicon and the Related Elements, 2008, vol. 183, # 8, p. 1870 - 1883
[48] Chemical and Pharmaceutical Bulletin, 2009, vol. 57, # 6, p. 557 - 560
[49] Synthesis, 2010, # 18, p. 3179 - 3187
[50] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 19, p. 5718 - 5721
[51] European Journal of Medicinal Chemistry, 2009, vol. 44, # 11, p. 4477 - 4484
[52] Journal of Heterocyclic Chemistry, 2010, vol. 47, # 1, p. 81 - 84
[53] Inorganic Chemistry Communications, 2010, vol. 13, # 5, p. 606 - 608
[54] European Journal of Medicinal Chemistry, 2010, vol. 45, # 11, p. 5353 - 5361
[55] European Journal of Medicinal Chemistry, 2011, vol. 46, # 5, p. 1897 - 1905
[56] Acta Poloniae Pharmaceutica - Drug Research, 2010, vol. 67, # 5, p. 567 - 573
[57] Organic Process Research and Development, 2010, vol. 14, # 6, p. 1490 - 1500
[58] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2011, vol. 50, # 9, p. 1202 - 1207
[59] Heterocyclic Communications, 2011, vol. 17, # 3-4, p. 111 - 119
[60] Dalton Transactions, 2011, vol. 40, # 37, p. 9370 - 9373
[61] E-Journal of Chemistry, 2010, vol. 7, # 4, p. 1196 - 1199
[62] Transition Metal Chemistry, 2011, vol. 36, # 5, p. 489 - 498
[63] Chinese Chemical Letters, 2012, vol. 23, # 3, p. 273 - 276
[64] Journal of the Serbian Chemical Society, 2012, vol. 77, # 3, p. 279 - 286
[65] Chinese Chemical Letters, 2012, vol. 23, # 4, p. 454 - 457
[66] Journal of Heterocyclic Chemistry, 2012, vol. 49, # 1, p. 80 - 87
[67] Journal of Chemical Sciences, 2011, vol. 123, # 5, p. 645 - 655
[68] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 11, p. 3816 - 3821
[69] Medicinal Chemistry Research, 2012, vol. 21, # 7, p. 1188 - 1198
[70] Journal of Chemical Sciences, 2012, vol. 124, # 3, p. 669 - 677
[71] European Journal of Medicinal Chemistry, 2012, vol. 54, p. 239 - 247
[72] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 1, p. 107 - 111
[73] Chinese Chemical Letters, 2012, vol. 23, # 12, p. 1367 - 1370
[74] Indian Journal of Heterocyclic Chemistry, 2011, vol. 21, # 1, p. 69 - 72
[75] Research on Chemical Intermediates, 2018, vol. 44, # 4, p. 2439 - 2449
[76] RSC Advances, 2018, vol. 8, # 43, p. 24376 - 24385
[77] Tetrahedron, 2013, vol. 69, # 10, p. 2309 - 2318
[78] Tetrahedron, 2013, vol. 69, # 16, p. 3451 - 3458
[79] Journal of Chemical Sciences, 2013, vol. 125, # 2, p. 321 - 333
[80] Journal of the Serbian Chemical Society, 2013, vol. 78, # 5, p. 621 - 625
[81] Tetrahedron, 2013, vol. 69, # 41, p. 8668 - 8674
[82] Medicinal Chemistry Research, 2014, vol. 23, # 1, p. 42 - 56
[83] Tetrahedron Letters, 2014, vol. 55, # 31, p. 4395 - 4399
[84] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 569 - 580
[85] Chinese Chemical Letters, 2014, vol. 25, # 7, p. 1073 - 1076
[86] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 205 - 212
[87] Journal of Sulfur Chemistry, 2018, vol. 39, # 4, p. 435 - 442
[88] Letters in Drug Design and Discovery, 2013, vol. 10, # 1, p. 75 - 85
[89] Letters in Organic Chemistry, 2014, vol. 11, # 10, p. 736 - 742
[90] Asian Journal of Chemistry, 2014, vol. 26, # 21, p. 7449 - 7451
[91] Chemical Communications, 2015, vol. 51, # 44, p. 9125 - 9128
[92] Journal of the Iranian Chemical Society, 2015, vol. 12, # 8, p. 1313 - 1324
[93] Journal of the Iranian Chemical Society, 2015, vol. 12, # 9, p. 1577 - 1584
[94] Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, vol. 31, p. 205 - 209
[95] Journal of Agricultural and Food Chemistry, 2015, vol. 63, # 23, p. 5587 - 5596
[96] Bulletin of the Korean Chemical Society, 2015, vol. 36, # 2, p. 719 - 722
[97] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 17, p. 3601 - 3605
[98] Organic and Biomolecular Chemistry, 2015, vol. 13, # 30, p. 8211 - 8220
[99] Research on Chemical Intermediates, 2015, vol. 41, # 8, p. 5509 - 5519
[100] Medicinal Chemistry Research, 2015, vol. 24, # 11, p. 3892 - 3911
[101] Research on Chemical Intermediates, 2015, vol. 41, # 11, p. 8381 - 8403
[102] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 24, p. 7629 - 7640
[103] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 9, p. 2278 - 2283
[104] Synthesis (Germany), 2016, vol. 48, # 14, p. 2178 - 2190
[105] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 7, p. 1696 - 1703
[106] European Journal of Medicinal Chemistry, 2017, vol. 141, p. 567 - 583
[107] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 13, p. 2244 - 2249
[108] European Journal of Medicinal Chemistry, 2018, vol. 157, p. 139 - 150
[109] MedChemComm, 2016, vol. 7, # 9, p. 1832 - 1848
[110] European Journal of Inorganic Chemistry, 2016, vol. 2016, # 26, p. 4199 - 4206
[111] Synthetic Communications, 2017, vol. 47, # 3, p. 224 - 231
[112] Medicinal Chemistry Research, 2017, vol. 26, # 1, p. 109 - 119
[113] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 1, p. 102 - 109
[114] Letters in Drug Design and Discovery, 2018, vol. 15, # 9, p. 914 - 922
[115] Dalton Transactions, 2017, vol. 46, # 15, p. 5069 - 5075
[116] Journal of Molecular Structure, 2017, vol. 1149, p. 439 - 451
[117] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 5, p. 2740 - 2747
[118] Synthetic Communications, 2017, vol. 47, # 20, p. 1884 - 1904
[119] Research on Chemical Intermediates, 2017, vol. 43, # 11, p. 6131 - 6154
  • 5
  • [ 612-62-4 ]
  • [ 73568-25-9 ]
YieldReaction ConditionsOperation in experiment
92% With n-butyllithium; diisopropylamine In tetrahydrofuran; <i>N</i>-methyl-acetamide; acetic acid EXAMPLE 7
2-Chloro-3-quinolinecarboxaldehyde
To a solution of 0.46 mL (3.30 mmol) of diisopropylamine in 8 mL of THF at 0° C. was added 1.53 mL (3.30 mmol) of n-BuLi dropwise.
After 20 min the solution was cooled to -78° C. and 2-chloroquinoline (491 mg, 3.0 mmol) was added neat.
The mixture was stirred at -78° C. for 30 min, then dimethylformamide (0.39 mL, 5.04 mmol) was added dropwise and the reaction mixture was stirred an additional 30 min at this temperature.
After quenching at -78° C. with glacial acetic acid (1 mL), the mixture was warmed to room temperature and diluted with ether (30 mL).
The organic phase was washed with saturated NaHCO3 solution (10 mL) and brine (10 mL), and was dried over MgSO4.
Concentration afforded 2-chloro-3-quinolinecarboxaldehyde (530 mg, 92percent) as a light yellow solid (mp 145°-149 ° C.), which was used directly in the next step without further purification.
Recrystallization from ethyl acetate afforded the pure compound as light yellow needles: mp 149°-150° C. (mp 148°-149° C. reported in Meth-Cohn, O.; Narhe, B.; Tarnowski, B. J. Chem. Soc. Perkin Trans. I 1981, 1520.).
1 H NMR (300 MHz, CDCl3) δ 10.57 (s, 1H), 8.77 (s, 1H), 8.08 (d, 1H, J=9 Hz), 8.0 (d, 1H, J=9 Hz), 7.90 (t, 1H, J=9 Hz), 7.67 (t, 1H, J=9 Hz); IR (nujol) 1685, 1575, 1045, 760, 745 cm-1.
92% With n-butyllithium; diisopropylamine In tetrahydrofuran; <i>N</i>-methyl-acetamide; acetic acid EXAMPLE 7
2-Chloro-3-quinolinecarboxaldehyde
To a solution of 0.46 mL (3.30 mmol) of diisopropylamine in 8 mL of THF at 0° C.
Was added 1.53 mL (3.30 mmol) of n-BuLi dropwise.
After 20 min the solution was cooled to -78° C. and 2-chloroquinoline (491 mg, 3.0 mmol) was added neat.
The mixture was stirred at -78° C. for 30 min, then dimethylformamide (0.39 mL, 5.04 mmol) was added dropwise and the reaction mixture was stirred an additional 30 min at this temperature.
After quenching at -78° C. with glacial acetic acid (1 mL), the mixture was warmed to room temperature and diluted with ether (30 mL).
The organic phase was washed with saturated NaHCO3 solution (10 mL) and brine (10 mL), and was dried over MgSO4.
Concentration afforded 2-chloro-3-quinolinecarboxaldehyde (530 mg, 92percent) as a light yellow solid (mp 145°-149 ° C.), which was used directly in the next step without further purification.
Recrystallization from ethyl acetate afforded the pure compound as light yellow needles: mp 149°-150° C. (mp 148°-149° C. reported in Meth-Cohn, O.; Narhe, B.; Tarnowski, B. J. Chem. Soc. Perkin Trans. I 1981, 1520.).
1H NMR (300 MHz, CDCl3) δ 10.57 (s, 1H), 8.77 (s, 1H), 8.08 (d, 1H, J=9 Hz), 8.0 (d, 1H, J=9 Hz), 7.90 (t, 1H, J=9 Hz), 7.67 (t, 1H, J=9 Hz); IR (nujol) 1685, 1575, 1045, 760, 745 cm-1.
Reference: [1] Patent: US5212317, 1993, A,
[2] Patent: US5162532, 1992, A,
  • 6
  • [ 103-84-4 ]
  • [ 73568-25-9 ]
YieldReaction ConditionsOperation in experiment
74% With trichlorophosphate In <i>N</i>-methyl-acetamide; ice-water EXAMPLE 8
Preparation of 2-Chloro-3-quinolinecarboxaldehyde from acetanilide
Following a literature procedure (see Meth-Cohn, O.; Narhe, B.; Tarnowski, B. J. Chem. Soc. Perkin Trans. I 1981, 1520), a phosphorus oxychloride (24.0 mL, 260 mmol) was added dropwise to an ice-cold solution of dimethylformamide (7.20 mL, 93.0 mmol) and the deep-red solution was stirred at 0° C. for 30 min.
Acetanilide (5.0 g, 37.0 mmol) was added neat and the mixture was stirred at 0° C. for 30 min., then heated at 75° C. for 16 h.
The cooled mixture was poured into 250 mL of ice-water and stirred at 0°-5° C. for 30 min.
The product was filtered, washed with water, and recrystallized from ethyl acetate to give 5.2 g (74percent) of 2-chloro-3-quinoline-carboxaldehyde as a light yellow solid: mp 147°-149° C.
74% With trichlorophosphate In <i>N</i>-methyl-acetamide; ice-water EXAMPLE 8
Preparation of 2-Chloro-3-quinoline-carboxaldehyde from acetanilide
Following a literature procedure (see Meth-Cohn, O.; Narhe, B.; Tarnowski, B. J. Chem. Soc. Perkin Trans. I 1981, 1520), phosphorus oxychloride (24.0 mL, 260 mmol) was added dropwise to an ice-cold solution of dimethylformamide (7.20 mL, 93.0 mmol) and the deep-red solution was stirred at 0° C. for 30 min.
Acetanilide (5.0 g, 37.0 mmol) was added neat and the mixture was stirred at 0° C. for 30 min, then heated at 75° C. for 16 h.
The cooled mixture was poured into 250 mL of ice-water and stirred at 0°-5° C. for 30 min.
The product was filtered, washed with water, and recrystallized from ethyl acetate to give 5.2 g (74percent) of 2-Chloro-3-quinoline-carboxaldehyde as a light yellow solid: mp 147°-149° C.
Reference: [1] Patent: US5212317, 1993, A,
[2] Patent: US5162532, 1992, A,
[3] Patent: US4735948, 1988, A,
[4] Patent: US4496569, 1985, A,
[5] Journal of Chemical Sciences, 2014, vol. 126, # 1, p. 205 - 212
  • 7
  • [ 103-84-4 ]
  • [ 73568-25-9 ]
YieldReaction ConditionsOperation in experiment
88% for 11 h; Reflux General procedure: To the prepared TCTA–DMFreagent, 9.8 mmol of the Acetanilide was added and stirred under refluxconditions. Progress of the reaction was checked by TLC till the completion ofthe reaction. Analytical TLC was carried out using Merck aluminum-backed0.2 mm silica gel 60 F-254 plates. Column chromatography was conductedusing Merck silica gel 60 (230–400 mesh). After completion of the reaction,water was added to the reaction mixture and stirred for a few more minutes toextract inorganic components into water. The organic layer was separated andthe crude product thus obtained was further purified with columnchromatography (silica gel, ethyl acetate/n-hexane)
Reference: [1] Tetrahedron Letters, 2015, vol. 56, # 37, p. 5164 - 5167
  • 8
  • [ 93299-49-1 ]
  • [ 73568-25-9 ]
Reference: [1] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1985, vol. 24, p. 1286 - 1287
  • 9
  • [ 613-91-2 ]
  • [ 68-12-2 ]
  • [ 73568-25-9 ]
Reference: [1] Journal of the Indian Chemical Society, 1990, vol. 67, # 8, p. 685 - 686
[2] Acta Poloniae Pharmaceutica - Drug Research, 2011, vol. 68, # 2, p. 231 - 236
[3] Journal of the Serbian Chemical Society, 2011, vol. 76, # 12, p. 1617 - 1626
[4] Acta Poloniae Pharmaceutica - Drug Research, 2013, vol. 70, # 3, p. 435 - 441
  • 10
  • [ 612-62-4 ]
  • [ 68-12-2 ]
  • [ 73568-25-9 ]
Reference: [1] Journal of Organic Chemistry, 2015, vol. 80, # 24, p. 12509 - 12525
  • 11
  • [ 62-53-3 ]
  • [ 73568-25-9 ]
Reference: [1] Heterocyclic Communications, 2011, vol. 17, # 3-4, p. 111 - 119
[2] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 635 - 646
[3] Medicinal Chemistry Research, 2013, vol. 22, # 2, p. 647 - 658
[4] Tetrahedron, 2013, vol. 69, # 41, p. 8668 - 8674
[5] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 2, p. 365 - 371
[6] Tetrahedron Letters, 2014, vol. 55, # 31, p. 4395 - 4399
[7] Journal of the Brazilian Chemical Society, 2014, vol. 25, # 7, p. 1253 - 1260
[8] European Journal of Medicinal Chemistry, 2014, vol. 83, p. 569 - 580
[9] Patent: WO2015/51149, 2015, A1,
[10] Journal of the Iranian Chemical Society, 2015, vol. 12, # 8, p. 1313 - 1324
[11] Journal of the Iranian Chemical Society, 2015, vol. 12, # 9, p. 1577 - 1584
[12] Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, vol. 31, p. 205 - 209
[13] Journal of Agricultural and Food Chemistry, 2015, vol. 63, # 23, p. 5587 - 5596
[14] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 17, p. 3601 - 3605
[15] Organic and Biomolecular Chemistry, 2015, vol. 13, # 30, p. 8211 - 8220
[16] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 24, p. 7629 - 7640
[17] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 9, p. 2278 - 2283
[18] MedChemComm, 2016, vol. 7, # 9, p. 1832 - 1848
[19] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 7, p. 1696 - 1703
[20] Molecules, 2016, vol. 21, # 7,
[21] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 1, p. 102 - 109
[22] Oriental Journal of Chemistry, 2016, vol. 32, # 4, p. 1977 - 1982
[23] Journal of Heterocyclic Chemistry, 2018, vol. 55, # 4, p. 1002 - 1009
[24] Bioorganic Chemistry, 2018, vol. 80, p. 591 - 601
  • 12
  • [ 125917-60-4 ]
  • [ 1972-28-7 ]
  • [ 73568-25-9 ]
  • [ 4114-28-7 ]
Reference: [1] Tetrahedron Letters, 2009, vol. 50, # 13, p. 1493 - 1494
  • 13
  • [ 137470-14-5 ]
  • [ 68-12-2 ]
  • [ 73568-25-9 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 128, p. 258 - 273
  • 14
  • [ 220248-42-0 ]
  • [ 73568-25-9 ]
Reference: [1] Synlett, 1999, # 1, p. 59 - 60
  • 15
  • [ 108-24-7 ]
  • [ 68-12-2 ]
  • [ 62-53-3 ]
  • [ 73568-25-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 5, p. 2740 - 2747
[2] ACS Combinatorial Science, 2017, vol. 19, # 8, p. 555 - 563
  • 16
  • [ 862249-68-1 ]
  • [ 109-94-4 ]
  • [ 73568-25-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 1589 - 1594
  • 17
  • [ 103-84-4 ]
  • [ 73568-25-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 2, p. 645 - 649
  • 18
  • [ 616882-50-9 ]
  • [ 73568-25-9 ]
  • [ 927891-86-9 ]
Reference: [1] Organic Letters, 2003, vol. 5, # 21, p. 3975 - 3978
  • 19
  • [ 91301-03-0 ]
  • [ 73568-25-9 ]
Reference: [1] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2005, vol. 44, # 9, p. 1868 - 1875
  • 20
  • [ 50314-86-8 ]
  • [ 68-12-2 ]
  • [ 73568-25-9 ]
Reference: [1] Heterocycles, 1984, vol. 21, # 2, p. 568
  • 21
  • [ 553-03-7 ]
  • [ 68-12-2 ]
  • [ 73568-25-9 ]
Reference: [1] Archiv der Pharmazie, 2011, vol. 344, # 10, p. 689 - 695
  • 22
  • [ 103-84-4 ]
  • [ 73568-25-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 22, p. 6097 - 6105
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 73568-25-9 ]

Chlorides

Chemical Structure| 73568-27-1

[ 73568-27-1 ]

2-Chloro-6-methylquinoline-3-carbaldehyde

Similarity: 0.90

Chemical Structure| 791626-59-0

[ 791626-59-0 ]

2-Chloroquinoline-6-carbaldehyde

Similarity: 0.90

Chemical Structure| 57876-69-4

[ 57876-69-4 ]

2-Chloro-3-methylquinoline

Similarity: 0.88

Chemical Structure| 4295-11-8

[ 4295-11-8 ]

2-Chloro-6-methylquinoline

Similarity: 0.82

Chemical Structure| 13669-68-6

[ 13669-68-6 ]

6-Chloroquinoline-3-carbaldehyde

Similarity: 0.82

Aldehydes

Chemical Structure| 73568-27-1

[ 73568-27-1 ]

2-Chloro-6-methylquinoline-3-carbaldehyde

Similarity: 0.90

Chemical Structure| 791626-59-0

[ 791626-59-0 ]

2-Chloroquinoline-6-carbaldehyde

Similarity: 0.90

Chemical Structure| 13669-68-6

[ 13669-68-6 ]

6-Chloroquinoline-3-carbaldehyde

Similarity: 0.82

Chemical Structure| 13669-42-6

[ 13669-42-6 ]

Quinoline-3-carboxaldehyde

Similarity: 0.81

Chemical Structure| 38707-70-9

[ 38707-70-9 ]

Quinoline-8-carbaldehyde

Similarity: 0.73

Related Parent Nucleus of
[ 73568-25-9 ]

Quinolines

Chemical Structure| 73568-27-1

[ 73568-27-1 ]

2-Chloro-6-methylquinoline-3-carbaldehyde

Similarity: 0.90

Chemical Structure| 791626-59-0

[ 791626-59-0 ]

2-Chloroquinoline-6-carbaldehyde

Similarity: 0.90

Chemical Structure| 57876-69-4

[ 57876-69-4 ]

2-Chloro-3-methylquinoline

Similarity: 0.88

Chemical Structure| 4295-11-8

[ 4295-11-8 ]

2-Chloro-6-methylquinoline

Similarity: 0.82

Chemical Structure| 13669-68-6

[ 13669-68-6 ]

6-Chloroquinoline-3-carbaldehyde

Similarity: 0.82